Skip to content

Treatment of Androgenetic Alopecia in Males and Females

The Growth of Human Scalp Hair Mediated By Visible Red Light Laser and LED Sources.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01437163
Acronym
LLLT
Enrollment
88
Registered
2011-09-20
Start date
2011-09-30
Completion date
2013-08-31
Last updated
2016-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic Alopecia

Brief summary

The purpose of this study is to evaluate the efficacy of Low Level Laser and Light Therapy system configured in a novel product called the TopHat 655 system, for promoting hair growth in males and females diagnosed with androgenetic alopecia of the head.

Interventions

DEVICETopHat 655 rejuvenation system

TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period

DEVICELaser and/or Light Hair Rejuvenation System

A red incandescent light source replaces all lasers and light emitting diodes.

Sponsors

Apira Science, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Diagnosis of androgenetic alopecia * Fitzpatrick Skin Phototypes I-IV * Norwood-Hamilton IIa to V for males and Ludwig I or II for females * Active hair loss within the last 12 months * Willingness to refrain from using all other hair growth products or treatments * In overall general good health as determined by the physician investigator

Exclusion criteria

* Photosensitivity to laser light and non-laser LED light operating at 655nms. * Malignancy in the target treatment area * Other forms of alopecia of the head * Past medical history of a collagen-vascular disease, thyroid disease or other cutaneous or systemic disease that seriously effects the scalp * Unwillingness to remove hair replacement products during the therapy sessions * Using any medications deemed to inhibit hair growth as determined by the physician investigator

Design outcomes

Primary

MeasureTime frame
Percentage Increase of Terminal Hairs from Pre-treatment, Baseline CountAfter 16 weeks of therapy

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026